Literature DB >> 24802288

Palmoplantar erythrodysesthesia-like skin symptoms in patients under various chemotherapeutics: preventive and therapeutic options.

Juergen Lademann1, Hans-Joachim Röwert-Huber, Norbert Haas, Franziska Kluschke, Alexa Patzelt, Leonhard Zastrow, Bernhard Lange-Asschenfeldt, Sora Jung, Wolfram Sterry, Jalid Sehouli.   

Abstract

BACKGROUND/AIMS: The palmoplantar erythrodysaesthesia (PPE) is an inflammatory cutaneous side effect in patients under chemotherapy with pegylated liposomal doxorubicin (PLD), with indications that also other chemotherapeutics induce similar side effects. Recently, it has been demonstrated that PLD escapes with the sweat onto the skin inducing radical-forming processes that damage the skin. The topical application of antioxidants with a high radical protection factor has proven to be a very efficient prevention strategy for PLD-treated patients.
METHODS: 68 patients, who had been treated with 12 different chemotherapeutics and experienced side effects similar to PPE, were treated with a meanwhile commercially available ointment.
RESULTS: At the beginning of the therapy, 46 patients suffered from a PPE of severity grade III, while in 22 patients a PPE of severity grade II was diagnosed. The application of the ointment resulted in a significant improvement of the clinical symptoms and the skin status in all these patients; their chemotherapies could be continued.
CONCLUSION: The obtained results suggest that radical-forming processes play an essential role in a great number of chemotherapeutics which induce dermal side effects. The topical application of the antioxidant-containing ointment proved to be a good therapeutic option which needs further evaluation.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24802288     DOI: 10.1159/000356780

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  1 in total

1.  Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).

Authors:  S Jung; J Sehouli; R Chekerov; F Kluschke; A Patzelt; H Fuss; F Knorr; J Lademann
Journal:  Support Care Cancer       Date:  2017-06-26       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.